Study of Ritlecitinib for Chronic Hives Not Helped by Antihistamines
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study is testing an experimental daily pill called ritlecitinib for adults whose chronic hives don’t go away with standard antihistamines. It may be a new option if your hives are active and you are not on omalizumab or are willing to stop it for several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had chronic spontaneous urticaria (unexplained hives that come and go) for at least 3 months.
- Your hives are still bothering you even after taking prescription antihistamines (like Zyrtec, Claritin, or Allegra) every day.
- You are willing to be off omalizumab (Xolair) for at least 4 months if you have used it before.
- You do not have other skin conditions that cause hives or itching (like vasculitis or atopic dermatitis).
- You have not had a recent or serious infection (like TB, shingles, hepatitis, or HIV) or are currently on strong antibiotics.
- You are over 18 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (HRS-3095) for chronic spontaneous urticaria—persistent hives that don't go away despite taking standard antihistamine pills. If your hives have lasted months and remain poorly controlled, this study may help you find relief.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
This trial tests a new medication (HS-10561) first in healthy adults to check safety, then in people with chronic spontaneous urticaria (long-term hives without a known cause) to see if it helps reduce symptoms. It may be an option for those who have had hives for at least 6 months.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.